The agency did not agree with Regeneron’s proposal to add dosing intervals greater than every 16 weeks, the maximum interval currently indicated for aflibercept 8 mg injections.
Eyenovia's late-stage study for near-sightedness in children with an experimental drug-device combination has been discontinued after failing to slow myopia progression, leading to consideration of strategic alternatives.
"Business owners can meet face-to-face with specialists to apply for disaster loans and access a wide range of resources to guide them through their recovery."
A groundbreaking late-stage study highlights the effectiveness of Viridian Therapeutics' novel treatment, veligrotug, for chronic thyroid eye disease, offering hope for more convenient and efficient therapy. Positive results led to a substantial boost in the company's stock price.